Recall: CyPass Micro-Stent Withdrawn Amid Concerns of Endothelial Cell Loss
August 29, 2018 — Alcon has issued a voluntary global recall of the CyPass microstent, effective immediately.
Menu
Menu
August 29, 2018 — Alcon has issued a voluntary global recall of the CyPass microstent, effective immediately.
A recent discovery from researchers at Massachusetts Eye and Ear and MIT is providing some new insights into what causes glaucoma.
Rhopressa 0.02% is a novel once-daily eye drop for lowering elevated intraocular pressure.
Researchers are working to overcome challenges to develop pilot teleglaucoma clinics in developing countries.
For the millions of people who currently live or will live with low vision, the good news is, there is help.
Glaucoma in developing countries represents a significant health crisis. …
What are the best kinds of charities to leave money to? What are signs an organization will put your money to good use? Here’s what to look for when choosing a charity to bequeath a legacy to.
On November 22, 2016, Allergan announced that the U.S. Food and Drug Administration (FDA) has cleared the XEN® Glaucoma Treatment System for use in the United States.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2023 all rights reserved.